Beyond Selective Serotonin Reuptake Inhibitor (SSRIs): Exploring Hormonal Therapy for Mood Disorders in Perimenopause and Postmenopause

超越选择性血清素再摄取抑制剂(SSRIs):探索围绝经期和绝经后情绪障碍的激素疗法

阅读:1

Abstract

Perimenopause and postmenopause are vulnerable periods for the onset or exacerbation of mood disorders due to fluctuating or persistently low estrogen levels and neurochemical changes. While antidepressants are often first-line treatments, a subset of women may benefit from hormone replacement therapy (HRT), particularly transdermal estradiol. This case report presents two women: one, aged 48, experiencing mood instability during perimenopause with pre-existing depression, and another, aged 55, who developed new-onset depressive symptoms during postmenopause. In both cases, treatment with estradiol alongside careful psychotropic management resulted in marked improvement. These cases highlight the utility of an integrative, hormone-informed approach in managing mood disorders during both perimenopause and postmenopause.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。